UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of Registrant as Specified in Its Charter)
|
|
|
|
|
(State or Other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
|
|
|
|
|
|
|
|
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s Telephone Number, Including Area Code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
|
|
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Results of Operations and Financial Condition.
(b) On November 13, 2020, Sandesh Mahatme informed Flexion Therapeutics, Inc. (the “Company”) that, due to his other full-time business commitments, he does not intend to stand for re-election to the Board of Directors at the Company’s 2021 Annual Meeting of Stockholders. Mr. Mahatme intends to continue serving as a member of the Company’s Board of Directors until the expiration of his term at the 2021 Annual Meeting of Stockholders.
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
Flexion Therapeutics, Inc. |
|
|
|
|
|
|
Date: November 19, 2020 |
By: |
/s/ Mark S. Levine |
|
|
|
Mark S. Levine |
|
|
|
General Counsel and Corporate Secretary |
2
Document and Entity Information |
Nov. 13, 2020 |
|---|---|
| Cover [Abstract] | |
| Entity Registrant Name | Flexion Therapeutics, Inc |
| Document Type | 8-K |
| Amendment Flag | false |
| Entity Central Index Key | 0001419600 |
| Document Period End Date | Nov. 13, 2020 |
| Entity Emerging Growth Company | false |
| Entity File Number | 001-36287 |
| Entity Incorporation State Country Code | DE |
| Entity Tax Identification Number | 26-1388364 |
| Entity Address, Address Line One | 10 Mall Road |
| Entity Address, Address Line Two | Suite 301 |
| Entity Address, City or Town | Burlington |
| Entity Address, State or Province | MA |
| Entity Address, Postal Zip Code | 01803 |
| City Area Code | (781) |
| Local Phone Number | 305-7777 |
| Written Communications | false |
| Soliciting Material | false |
| Pre Commencement Tender Offer | false |
| Pre Commencement Issuer Tender Offer | false |
| Security 12b Title | Common Stock, par value $0.001 per share |
| Trading Symbol | FLXN |
| Security Exchange Name | NASDAQ |